ChemicalBook > Product Catalog >API >Circulatory system drugs >Anti-atherosclerotic Drugs >Ezetimibe


Ezetimibe Suppliers list
Company Name: Nanjing Gold Pharmaceutical Technology Co. Ltd.
Tel: 025-84209270 15906146951
Products Intro: Product Name:Ezetimibe
Purity:99% Package:1000KG;;100KG;10KG;5KG;1KG
Company Name: Beijing Cooperate Pharmaceutical Co.,Ltd
Tel: 010-60279497
Products Intro: Product Name:Ezetimibe
Purity:98% Package:100G;1KG;5KG;10KG;25KG;50KG;100KG
Company Name: Casorganics US Corp
Tel: +17326109938
Products Intro: Product Name:Ezetimibe
Purity:99.98% Package:1KG;USD|5KG;USD|25KG;USD
Company Name: Capot Chemical Co.,Ltd.
Tel: +86-571-85586718
Products Intro: Product Name:1-(4-Fluorophenyl)-3-[3-(4-fluorophenyl)-3-hydroxy-propyl]-4-(4-hydroxyphenyl)-azetidin-2-one
Purity:98%(Min.HPLC) Package:100g;1kg;5kg,10kg,25kg,50kg
Company Name: Henan Tianfu Chemical Co.,Ltd.
Tel: 0371-55170693
Products Intro: Product Name:Ezetimibe
Purity:0.99 Package:25KG,5KG;1KG;500G

Lastest Price from Ezetimibe manufacturers

  • Ezetimibe
  • US $0.00 / KG
  • 2020-10-22
  • CAS:163222-33-1
  • Min. Order: 100g
  • Purity: 98%+
  • Supply Ability: 100kg
  • Ezetimibe
  • 2020-07-21
  • CAS:163222-33-1
  • Min. Order: 1ASSAYS
  • Purity: 99%min
  • Supply Ability: 20Ton
  • EzetiMibe
  • US $1.00 / KG
  • 2020-05-12
  • CAS: 163222-33-1
  • Min. Order: 1KG
  • Purity: 99%
  • Supply Ability: 20T

Related articles

Ezetimibe Basic information
Description Indications and Usage Mechanisms of Action References
Product Name:Ezetimibe
Synonyms:(3R,4S)-1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphenyl)azetidin-2-one;Ezetimibe-001;Ticagrelor and its interMediate;Ezetimibe 1-(4-Fluorophenyl)-3-[3-(4-fluorophenyl)-3-hydroxy-propyl]-4-(4-hydroxyphenyl)-azetidin-2-one;Ezatimibe;zetia/vytorin;SCH 60969;Ezetimibe, >=99%
Product Categories:Isotope;CEDAX;Final material;API;Ezetimibe;Cardiovascular APIs;All Inhibitors;Inhibitors;Intermediates & Fine Chemicals;Pharmaceuticals
Mol File:163222-33-1.mol
Ezetimibe Structure
Ezetimibe Chemical Properties
Melting point 164-166°C
alpha D22 -33.9° (c = 3 in methanol)
Boiling point 654.9±55.0 °C(Predicted)
density 1.334±0.06 g/cm3(Predicted)
storage temp. -20?C Freezer
form powder
CAS DataBase Reference163222-33-1(CAS DataBase Reference)
EPA Substance Registry System2-Azetidinone, 1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphenyl)-, (3R,4S)- (163222-33-1)
Safety Information
Risk Statements 36/37/38
Safety Statements 26-36-24/25
HS Code 29337900
MSDS Information
Ezetimibe Usage And Synthesis
DescriptionEzetimibe is ananti-hyperlipidemic drug used for lowering the plasma cholesterol levels. It is indicated as an adjunctive therapy to diet for the reduction of high-level total-C, LDL-C, and ApoB in patients suffering primary (heterozygous familial and non-familial) hypercholesterolemia. It is also used in combination therapy with HMG-CoA reductase inhibitors.Ezetimibe does not inhibit the cholesterol synthesis in the liver, or increase bile acid excretion.It takes effect throughacting at the brush border of the small intestine and inhibiting the absorption of cholesterol, further leading to a decrease in the delivery of intestinal cholesterol to the liver. This causes a reduction of hepatic cholesterol stores and an increase in clearance of blood cholesterol.
Indications and UsageEzetimibe is a new form of selective cholesterol absorption inhibitor developed in a collaboration between Schering-Plough Co. and Merck Co. This drug is the first cholesterol absorption selective inhibitor to be approved for sale by the American FDA. Its commercial name is Ezetrol.
This drug can be used alone or in combination with HMG-CoA reductase inhibitors (statins) to treat primary (heterozygous familial and non-familial) hypercholesterolemia, homozygous familial hypercholesterolemia (HoFH), homozygous viremia (or phytosterolemia).
Mechanisms of ActionEzetimibe’s mechanisms of action are different from those of other lipid-lowering drugs (such as statins, cholic acid chelating agents, phenoxy acid derivatives, and plant sterols). This drug binds with the surface proteins on the brush border membrane vesicles of the small intestine (relative molecular mass 145x10^3) to inhibit the small intestine’s absorption of cholesterol in food and bile, thus decreasing the cholesterol content in serum and the liver. Ezetimibe is different from bile acid sequestrants because it does not affect the absorption of cholesterol esters, other steroids (such as bezoar and cholic acid), three triacylglycerol, and fat-soluble vitamins. Its effects are unrelated to whether or not acetyl coenzyme A- cholesterol acetyltransferase (ACAT) is inhibited or whether or not the LDL receptor (scavenger receptor) is expressed. After Ezetimibe is absorbed and binds with glucuronic acid in the liver, it undergoes enterohepatic circulation and almost exclusively targets small intestine mucosa cells.
Davidson, Michael H, et al. "Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia ☆." Journal of the American College of Cardiology 40.12(2002):2125.
Sudhop, T, et al. "Inhibition of intestinal cholesterol absorption by ezetimibe in humans. " Circulation 106.15(2002):1943-8.
DescriptionEzetimibe is a once-daily orally active cholesterol absorption inhibitor, launched as a hypolipidemic agent. The one-step diastereo- and enantioselective formation of β-lactams starting from commercially available (3S)-hydroxy-y-lactone is the key point of the asymmetric synthesis of ezetimibe. The 2-azetidinone class was initially designed as acylcoenzyme A: cholesterol acyltransferase (ACAT) inhibitors but experimental data suggest that this compound acts in the intestinal wall to inhibit cholesterol through a novel mechanism with an as yet undiscovered target. Orally administered ezetimibe inhibited increases in plasma cholesterol in four cholesterol-fed animals species (hamster, rats, dogs and rhesus monkeys). In rats cannulated in the intestine and bile duct, [3H]-ezetimibe inhibited cholesterol absorption by more than 95%. In cholesterol-fed LDL receptor+apoE knockout mice, treatment with ezetimibe reduced atherosclerotic lesion cross sectional area by 48% in the aorta and 20% in the carotid artery. Moreover, the plasma cholesterol levels were reduced and the progression of lesions was inhibited. Ezetimibe is highly protein bound and is metabolized by the liver to its glucuronide metabolite, which represents 80-90% of circulating ezetimibe. About 90% of ezetimibe and/or the glucuronide metabolite are excreted in the feces and 10% in the urine. The parent compound and its glucuronide metabolite undergo enterohepatic recirculation; in consequence, the drug is slowly eliminated. In hypercholesterolemic patients, ezetimibe (10 mglday, 12 weeks) reduced LDL cholesterol by 18% and total cholesterol by 12%, with a similar safety profile to placebo. Co-administration of ezetimibe with statins or fenofibrate lowered LDL cholesterol levels more than either monotherapy. Ezetimibe was well tolerated and interaction studies provided evidence that ezetimibe had no significant effect on the activity of major CYP450 drug-metabolizing enzymes. Moreover, no pharmacokinetic/pharmacodynamic interactions were seen between ezetimibe and statins and others frequently administered drugs. .
Chemical PropertiesWhite Solid
OriginatorSchering-Plough (USA)
UsesAn antihyperlipoproteinemic. A Cholesterol absorption inhibitor
UsesA cholesterol transport inhibitor that binds to NPC1L1
UsesFor use as adjunctive therapy to diet for the reduction of elevated total-C, LDL-C, and Apo B in patients with primary (heterozygous familial and non-familial) hypercholesterolemia.
Brand nameZetia (Merck/Schering-Pough);Ezetrol.
Biological FunctionsEzetimibe lowers plasma cholesterol levels by inhibiting the absorption of cholesterol at the brush border of the small intestine. Specifically, it has been proposed to bind to a specific transport protein located in the wall of the small intestine, resulting in a reduction of cholesterol transport and absorption. Ezetimibe appears to be selective in its actions in that it does not interfere with the absorption of triglycerides, lipid-soluble vitamins or other nutrients. The decreased absorption of cholesterol eventually leads to enhanced receptor-mediated LDL uptake similar to that seen with bile acid sequestrants and HMGRIs. When used as monotherapy, the decreased absorption of cholesterol causes a compensatory increase in cholesterol biosynthesis. This is similar to that described for bile acid sequestrants and is insufficient to override the overall LDL lowering effects of ezetimibe.
General DescriptionEzetimibe, (3R,4S)-1-(4-fluorophenyl)-3-((3S)-3-(4-fluorophenyl)-3-hydroxypropyl)-4-(4-hydroxyphenyl)-2-azetidinone (Zetia), is an antihyperlipidemicagent that has usefulness in lowering cholesterol levels. Itacts by decreasing cholesterol absorption in the intestine byblocking the absorption of the sterol at the Brush boarder.Specifically, the -lactam binds to the Niemann-Pick C1-Like 1 (NPC1L1) protein on the gastrointestinal tract that isresponsible for cholesterol absorption. Although it may beused alone, it is marketed as a combination product withsimvastatin under the trade name Vytorin.
PharmacokineticsEzetimibe is administered orally; however, its absolute bioavailability cannot be determined because of its aqueous insolubility and the lack of an injectable formulation. Based on area under the curve values, the oral absorption ranges from 35 to 60%. Mean peak concentrations of the active glucuronidated metabolite are reached within 1 to 2 hours. Both ezetimibe and its glucuronide conjugate are extensively bound (>90%) to plasma proteins. The relative plasma concentrations of ezetimibe and its glucuronide conjugate range from 10 to 20% and from 80 to 90%, respectively. Both compounds have a long half-life of approximately 22 hours. The coadministration of food with ezetimibe has no effect on the extent of absorption.
Clinical UseEzetimibe is indicated as monotherapy or in combination with an HMGRI for the reduction of elevated total cholesterol, LDL cholesterol, and apoB in patients with primary (heterozygous familial and nonfamilial) hypercholesterolemia. When used as monotherapy, ezetimibe reduces LDL cholesterol by approximately 18%. When used in combination therapy with an HMGRI, LDL levels are reduced by 25 to 65% depending on the dose of the HMGRI inhibitor. Ezetimibe also is indicated for homozygous familial hypercholesterolemia in combination with either atorvastatin or simvastatin and for homozygous familial sitosterolemia. All indications are for patients who have not responded to diet, exercise, and other nonpharmacological methods.
Side effectsEzetimibe generally is well tolerated. The most common adverse effects are listed above. Whenever ezetimibe is used in combination with an HMGRI, the incidence of myopathy or rhabdomyolysis does not increase above that seen with HMGRI monotherapy.
MetabolismFollowing oral administration, ezetimibe is rapidly and extensively metabolized in the intestinal wall and the liver to its active metabolite, a corresponding phenol glucuronide. This glucuronide is reexcreted in the bile back to its active site. A small amount (<5%) of ezetimibe undergoes oxidation to covert the benzylic hydroxyl group to a ketone; however, ezetimibe does not appear to exert any significant effect on the activity of CYP450 enzymes.
Ezetimibe Preparation Products And Raw materials
Tag:Ezetimibe(163222-33-1) Related Product Information
4-Difluoromethoxy-3-hydroxybenzaldehyde (4S)-3-[5-(4-Fluorophenyl)-1,5-dioxopenyl]-4-phenyl-2-oxazolidinone Methyl (3R,4S)-1-(4-fluorophenyl)-2-oxo-4-[4-(phenylmethoxy)phenyl]-3-azetidinepropanoate EZETIMIBE PHENOXY GLUCURONIDE,Ezetimibe -D-Glucuronide, >85%,EZETIMIBE B-D-GLUCURONIDE (3R,4S)-4-(4-(Benzyloxy)Phenyl)-1-(4-Fluorophenyl)-3-((S)-3-(4- Fluorophenyl)-3-Hydroxypropyl)Azetidin-2-One EZETIMIBE 2,3,4-TRI-O-ACETYL-B-D-GLUCURONIDE METHYL ESTER EZETIMIBE HYDROXY GLUCURONIDE,Ezetimibe Hydroxy b-D-Glucuronide,Ezetimibe Hydroxy -D-Glucuronide Ezetimibe-13C6 N,N-Dimethylformamide Propyl butyrate Isopropyl alcohol Polyacrylamide Acrylamide Nicotinamide Etimicin POLY(N-ISOPROPYL ACRYLAMIDE) CHLOROPHOSPHONAZO III Ezetimibe